Holders — by stockHoldings — by fund
Saturn V Capital Management LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001964437
$697.5M
disclosed book value
23
positions
11.9%
largest position share
Positions, as of 2026-06-30
top 23 of 23 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | AMLXAMYLYX PHARMACEUTICALS INC | 4.6M | $83.0M | 11.9% |
| 2 | ALMSALUMIS INC | 2.9M | $82.0M | 11.8% |
| 3 | ABVXABIVAX SA | 518,865 | $69.1M | 9.9% |
| 4 | PCVXVAXCYTE INC | 852,914 | $49.6M | 7.1% |
| 5 | IMMXIMMIX BIOPHARMA INC | 4.7M | $48.0M | 6.9% |
| 6 | PHARVARIS N V | 1.3M | $45.4M | 6.5% |
| 7 | JAZZ PHARMACEUTICALS PLC | 160,938 | $38.8M | 5.6% |
| 8 | CELCCELCUITY INC | 370,318 | $38.7M | 5.6% |
| 9 | IRONDISC MEDICINE INC | 524,730 | $38.4M | 5.5% |
| 10 | CADLCANDEL THERAPEUTICS INC | 3.3M | $34.0M | 4.9% |
| 11 | XFORX4 PHARMACEUTICALS INC | 7.0M | $32.6M | 4.7% |
| 12 | MNPRMONOPAR THERAPEUTICS INC | 311,976 | $28.9M | 4.1% |
| 13 | DYNDYNE THERAPEUTICS INC | 1.1M | $23.5M | 3.4% |
| 14 | TRVITREVI THERAPEUTICS INC | 1.1M | $19.6M | 2.8% |
| 15 | ZURA BIO LTD | 2.1M | $12.4M | 1.8% |
| 16 | SGMTSAGIMET BIOSCIENCES INC | 1.5M | $11.4M | 1.6% |
| 17 | OCULIS HOLDING AG | 684,880 | $9.5M | 1.4% |
| 18 | IKTINHIBIKASE THERAPEUTICS INC | 3.9M | $7.9M | 1.1% |
| 19 | VIRVIR BIOTECHNOLOGY INC | 770,643 | $7.9M | 1.1% |
| 20 | IVVDINVIVYD INC | 8.4M | $7.3M | 1% |
| 21 | ANROALTO NEUROSCIENCE INC | 182,829 | $4.8M | 0.7% |
| 22 | MSLESATELLOS BIOSCIENCE INC | 350,000 | $2.7M | 0.4% |
| 23 | OVIDOVID THERAPEUTICS INC | 663,060 | $1.8M | 0.3% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.